Lee Ainslie’s Puma Biotechnology PBYI Stock Holding History

Lee Ainslie’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,720	Closed	-$48K	–	830
2020 Q4	$48K	Buy	+4,720	New	+$47.8K	﹤0.01%	624

Other funds holding PBYI

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Lee Ainslie's PBYI Position: Q1 2021 in Review

Lee Ainslie sold out of Puma Biotechnology (PBYI) in Q1 2021, closing a stake of 4,720 shares — an estimated $48K sold.

Lee Ainslie first reported a position in PBYI in Q4 2020 and held it in 1 quarter. The position peaked at $48K in Q4 2020. 118 funds tracked by Wall St. Rank hold PBYI as of Q1 2021.

Lee Ainslie reported no remaining Puma Biotechnology position as of Q1 2021 after selling out during the quarter.
Lee Ainslie sold 4,720 Puma Biotechnology shares in Q1 2021, an estimated $48K.
Lee Ainslie first reported a position in Puma Biotechnology in Q4 2020 and held it in 1 quarter.
Lee Ainslie's Puma Biotechnology position peaked at $48K in Q4 2020.
118 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2021.

Based on Maverick Capital's 13F filing for Q1 2021, filed 17 May 2021.